Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Hormone. Texas Oncology and US Oncology Research, Webster, TX, United States



Survival: 18.1 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
Hormone
   
Drugs:
Country: United States
   
City/State/Province: Webster, TX
   
Hospital: Texas Oncology and US Oncology Research
   
Journal: Link
   
Date: 11/2011

Description:
Patients:
This phase II study involved men with metastatic castration-resistant prostate cancer who were separated into two separate treatment groups. Group A had 110 patients with a median age of 69.0 years. Group B also had 110 patients with a median age of 69.5 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel, the hormone prednisone, and the biologic therapy agent AT-101, which inhibits a protein, Bcl-2, that prevents cell death.

Patients in group B were treated with the chemotherapy agent docetaxel and the hormone prednisone.

Toxicities:
The most severe adverse events in group A were of grade 4, including neutropenia, pulmonary embolism, fatigue, and anemia.

The most severe adverse events in group B were of grade 4, including neutropenia, deep vein thrombosis, and leucopenia.

Results:
The median overall survival rates for groups A and B were 18.1 and 17.8 months, respectively.

Support:
This study was supported by Ascenta Therapeutics.

Correspondence: Dr. G. Sonpavde; email: guru.sonpavde@usoncology.com

E-mail to a Friend Email Physician More Information